Robeco Institutional Asset Management B.V. Acquires 26,801 Shares of Pfizer Inc. (PFE)

Robeco Institutional Asset Management B.V. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 0.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,288,226 shares of the biopharmaceutical company’s stock after purchasing an additional 26,801 shares during the quarter. Pfizer accounts for approximately 0.7% of Robeco Institutional Asset Management B.V.’s investment portfolio, making the stock its 29th largest position. Robeco Institutional Asset Management B.V. owned 0.06% of Pfizer worth $117,387,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of PFE. Shine Investment Advisory Services Inc. purchased a new position in Pfizer during the second quarter worth $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer during the second quarter worth $103,000. D. Scott Neal Inc. boosted its stake in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC purchased a new position in Pfizer during the second quarter worth $120,000. Finally, Private Vista LLC boosted its stake in Pfizer by 2,277.3% during the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 190,933 shares during the period. 69.75% of the stock is owned by hedge funds and other institutional investors.

Shares of Pfizer Inc. (NYSE:PFE) opened at $36.24 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $216,020.00, a PE ratio of 14.78, a P/E/G ratio of 2.61 and a beta of 1.01. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $37.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share. research analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. The ex-dividend date is Thursday, February 1st. Pfizer’s payout ratio is presently 78.53%.

Pfizer announced that its board has authorized a stock repurchase plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Several analysts have recently weighed in on PFE shares. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Berenberg Bank set a $36.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, October 31st. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Buy” and a consensus target price of $38.77.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Insiders sold 36,800 shares of company stock valued at $1,327,248 over the last 90 days. 0.06% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Robeco Institutional Asset Management B.V. Acquires 26,801 Shares of Pfizer Inc. (PFE)” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/12/22/robeco-institutional-asset-management-b-v-acquires-26801-shares-of-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit